Pyxis Oncology ratios data for the quarter ended Jun 2026. These financial ratios cover 19 quarters of results from Sep 2021 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | |||||||||||||||||||
| Gross Margin | 97.06% | 100.00% | 78.37% | ||||||||||||||||
| EBT Margin | -24.80% | -640.82% | -154.04% | ||||||||||||||||
| EBIT Margin | -34.71% | -700.35% | -165.75% | ||||||||||||||||
| EBITDA Margin | -34.71% | -700.35% | -165.75% | ||||||||||||||||
| Operating Margin | -34.71% | -700.35% | -165.75% | ||||||||||||||||
| Net Margin | -24.80% | -650.85% | -2.75% | ||||||||||||||||
| FCF Margin | -129.73% | -612.16% | -94.46% | ||||||||||||||||
| Efficiency | |||||||||||||||||||
| Assets AverageAssets Avg. | 209.75M | 266.36M | 247.63M | 233.23M | 217.64M | 197.09M | 179.02M | 180.96M | 180.21M | 196.97M | 214.30M | 201.85M | 176.25M | 146.52M | 129.54M | 114.41M | 98.56M | 73.22M | |
| Invested CapitalInvested Cap. | -62.32M | ||||||||||||||||||
| Asset Utilization RatioAsset Util. | 0.09 | 0.02 | 0.02 | 0.14 | 0.19 | ||||||||||||||
| Leverage & Solvency | |||||||||||||||||||
| Debt Ratio | 0.07 | ||||||||||||||||||
| Valuation | |||||||||||||||||||
| Price to EarningsP/E | -5.67 | -4.17 | -3.02 | -2.32 | -1.30 | -7.68 | -6.12 | -3.73 | -4.98 | -62.55 | -11.27 | -10.29 | -2.63 | -2.79 | -3.72 | -6.27 | -237.93 | -7.53 | |
| Price to SalesP/S | 15.51 | 24.19 | 6.53 | ||||||||||||||||
| Price to BookP/B | 0.36 | 0.56 | 0.36 | 0.34 | 0.29 | 0.97 | 0.69 | 0.64 | 0.64 | 1.36 | 1.15 | 1.42 | 0.77 | 0.59 | 0.78 | 2.01 | 1.35 | 16.69 | |
| Enterprise Value | -183.04M | -117.76M | -147.52M | -135.81M | -133.92M | -1.31M | -41.86M | -44.82M | -38.74M | 93.47M | 39.28M | 73.36M | -33.38M | -45.03M | -20.72M | 61.72M | 5.24M | 157.94M | |
| EV to EBIT | 11.14 | 3.75 | 5.73 | 4.78 | 3.53 | 0.06 | 2.31 | 1.77 | 2.18 | -16.68 | -1.96 | -3.09 | 0.83 | 1.97 | 1.05 | -2.63 | -0.29 | -6.08 | |
| EV to EBITDA | 11.14 | 3.75 | 5.73 | 4.78 | 3.53 | 0.06 | 2.31 | 1.77 | 2.18 | -16.68 | -1.96 | -3.09 | 0.83 | 1.97 | 1.05 | -2.63 | -0.29 | -6.08 | |
| Market Capitalization | 93.17M | 130.79M | 77.31M | 64.20M | 46.84M | 148.04M | 100.80M | 88.15M | 80.56M | 250.50M | 195.01M | 218.18M | 93.55M | 60.40M | 68.22M | 137.97M | 72.09M | 190.94M | |
| Price to FCFP/FCF | -7.66 | -4.67 | -3.27 | -2.59 | -2.43 | -4.74 | -7.59 | -5.00 | -5.28 | -11.96 | -64.85 | -14.88 | -4.85 | -2.68 | -3.95 | -10.39 | -6.91 | ||
| EV to FCF | 15.04 | 4.20 | 6.24 | 5.47 | 6.96 | 0.04 | 3.15 | 2.54 | 2.54 | -4.46 | -13.06 | -5.00 | 1.73 | 2.00 | 1.20 | -4.65 | -0.50 | ||
| EV to CFO | 15.04 | 4.25 | 6.22 | 6.61 | 7.70 | 0.05 | 3.79 | 2.55 | 2.54 | -4.51 | -13.06 | -5.00 | 1.73 | 2.00 | 1.20 | -4.65 | -0.50 | ||
| Return Ratios | |||||||||||||||||||
| Return on Sales [ROS]ROS | -34.71% | -554.07% | -700.35% | -3,765.74% | -165.75% | -631.38% | |||||||||||||
| Return on Capital Employed [ROCE]ROCE | -36.49% | -26.45% | -36.59% | -47.60% | -66.39% | -60.94% | -62.10% | -67.09% | -53.22% | -36.56% | -34.83% | -37.00% | -56.42% | -80.83% | -95.19% | -111.75% | -109.03% | -191.26% | |
| Return on Assets [ROA]ROA | -33.23% | -24.53% | -34.32% | -43.32% | -55.47% | -55.11% | -55.59% | -52.77% | -41.93% | -30.61% | -28.52% | -29.07% | -44.30% | -65.35% | -74.73% | -85.31% | -63.24% | -90.15% |